dc.contributor
Institut Català de la Salut
dc.contributor
[Sharma M] Department of Medicine (Neurology), McMaster University, Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada. [Smith EE] Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. [Pearce LA] St. Catharines, Ontario, Canada. [Perera KS] Department of Medicine (Neurology), McMaster University, Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada. [Kasner SE] Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. [Yoon BW] Department of Neurology, Seoul National University Hospital, Seoul, Korea. [Puig J] Department of Radiology, Girona Biomedical Research Institute, Hospital Universitari de Girona Dr. Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain
dc.contributor
Departament de Salut
dc.contributor.author
Sharma, Mukul
dc.contributor.author
Smith, Eric
dc.contributor.author
Pearce, Lesly
dc.contributor.author
Perera, Kanjana
dc.contributor.author
Kasner, Scott
dc.contributor.author
Yoon, Byung Woo
dc.contributor.author
Puig, Josep
dc.date.accessioned
2025-10-24T07:47:09Z
dc.date.available
2025-10-24T07:47:09Z
dc.date.issued
2024-03-14T11:26:30Z
dc.date.issued
2024-03-14T11:26:30Z
dc.identifier
Sharma M, Smith EE, Pearce LA, Perera KS, Kasner SE, Yoon BW, et al. Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. Int J Stroke. 2022 Aug;17(7):799-805.
dc.identifier
https://hdl.handle.net/11351/11192
dc.identifier
10.1177/17474930211058012
dc.identifier.uri
https://hdl.handle.net/11351/11192
dc.description.abstract
Rivaroxabán; Aspirina; Infart cerebral
dc.description.abstract
Rivaroxabán; Aspirina; Infarto cerebral
dc.description.abstract
Rivaroxabán; Aspirin; Brain infarct
dc.description.abstract
Background: Covert brain infarcts are associated with important neurological morbidity. Their incidence in patients with embolic stroke of undetermined source (ESUS) is unknown.
Aims: To assess the incidence of covert brain infarcts and cerebral microbleeds using MRI in a prospective substudy of the NAVIGATE ESUS randomized trial and to evaluate the effects of antithrombotic therapies.
Methods: At 87 sites in 15 countries, substudy participants were randomly assigned to receive rivaroxaban 15 mg daily or aspirin 100 mg daily and underwent brain MRI near randomization and after study termination. The primary outcome was incident brain infarct (clinical ischemic stroke or covert brain infarct). Brain infarcts and microbleeds were ascertained centrally by readers unaware of treatment. Treatment effects were estimated using logistic regression.
Results: Among the 718 substudy participants with interpretable, paired MRIs, the mean age was 67 years and 61% were men with a median of 52 days between the qualifying ischemic stroke and randomization and a median of seven days between randomization and baseline MRI. During the median (IQR) 11 (12) month interval between scans, clinical ischemic strokes occurred in 27 (4%) participants, while 60 (9%) of the remaining participants had an incident covert brain infarct detected by MRI. Assignment to rivaroxaban was not associated with reduction in the incidence of brain infarct (OR 0.77, 95% CI 0.49, 1.2) or of covert brain infarct among those without clinical stroke (OR 0.85, 95% CI 0.50, 1.4). New microbleeds were observed in 7% and did not differ among those assigned rivaroxaban vs. aspirin (HR 0.95, 95% CI 0.52-1.7).
Conclusions: Incident covert brain infarcts occurred in twice as many ESUS patients as a clinical ischemic stroke. Treatment with rivaroxaban compared with aspirin did not significantly reduce the incidence of covert brain infarcts or increase the incidence of microbleeds, but the confidence intervals for treatment effects were wide.Registration: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.
dc.description.abstract
The NAVIGATE ESUS trial and the MRI Substudy were sponsored by Bayer AG.
dc.format
application/pdf
dc.publisher
Sage Publications
dc.relation
International Journal of Stroke;17(7)
dc.relation
https://doi.org/10.1177/17474930211058012
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Anticoagulants
dc.subject
Infart cerebral
dc.subject
CHEMICALS AND DRUGS::Organic Chemicals::Sulfur Compounds::Thiophenes::Rivaroxaban
dc.subject
CHEMICALS AND DRUGS::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Benzene Derivatives::Phenols::Hydroxybenzoates::Salicylates::Aspirin
dc.subject
DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Brain Ischemia::Brain Infarction
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::compuestos de azufre::tiofenos::rivaroxabán
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::hidrocarburos::hidrocarburos cíclicos::hidrocarburos aromáticos::derivados del benceno::fenoles::hidroxibenzoatos::salicilatos::aspirina
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos cerebrovasculares::isquemia cerebral::infarto encefálico::infarto cerebral
dc.title
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy
dc.type
info:eu-repo/semantics/article
